Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1976 1
1979 3
1981 2
1982 1
1983 2
1984 2
1985 4
1986 3
1987 5
1988 3
1989 8
1990 8
1991 15
1992 16
1993 6
1994 17
1995 12
1996 28
1997 23
1998 24
1999 25
2000 35
2001 32
2002 37
2003 48
2004 46
2005 46
2006 61
2007 65
2008 78
2009 94
2010 103
2011 107
2012 113
2013 151
2014 158
2015 172
2016 264
2017 308
2018 323
2019 330
2020 401
2021 414
2022 374
2023 353
2024 142

Text availability

Article attribute

Article type

Publication date

Search Results

3,797 results

Results by year

Filters applied: . Clear all
Page 1
Update on treatments for nonmotor symptoms of Parkinson's disease-an evidence-based medicine review.
Seppi K, Ray Chaudhuri K, Coelho M, Fox SH, Katzenschlager R, Perez Lloret S, Weintraub D, Sampaio C; the collaborators of the Parkinson's Disease Update on Non-Motor Symptoms Study Group on behalf of the Movement Disorders Society Evidence-Based Medicine Committee. Seppi K, et al. Mov Disord. 2019 Feb;34(2):180-198. doi: 10.1002/mds.27602. Epub 2019 Jan 17. Mov Disord. 2019. PMID: 30653247 Free PMC article. Review.
OBJECTIVE: To update evidence-based medicine recommendations for treating nonmotor symptoms in Parkinson's disease (PD). BACKGROUND: The International Parkinson and Movement Disorder Society Evidence-Based Medicine Committee's recommendations for treatments of PD we …
OBJECTIVE: To update evidence-based medicine recommendations for treating nonmotor symptoms in Parkinson's disease (PD). BACKGROUND: The Int …
Diagnostic criteria for mild cognitive impairment in Parkinson's disease: Movement Disorder Society Task Force guidelines.
Litvan I, Goldman JG, Tröster AI, Schmand BA, Weintraub D, Petersen RC, Mollenhauer B, Adler CH, Marder K, Williams-Gray CH, Aarsland D, Kulisevsky J, Rodriguez-Oroz MC, Burn DJ, Barker RA, Emre M. Litvan I, et al. Mov Disord. 2012 Mar;27(3):349-56. doi: 10.1002/mds.24893. Epub 2012 Jan 24. Mov Disord. 2012. PMID: 22275317 Free PMC article. Review.
Mild cognitive impairment is common in nondemented Parkinson's disease (PD) patients and may be a harbinger of dementia. In view of its importance, the Movement Disorder Society commissioned a task force to delineate diagnostic criteria for mild cognitive impairment …
Mild cognitive impairment is common in nondemented Parkinson's disease (PD) patients and may be a harbinger of dementia. In view of its impo …
Movement disorders with neuronal antibodies: syndromic approach, genetic parallels and pathophysiology.
Balint B, Vincent A, Meinck HM, Irani SR, Bhatia KP. Balint B, et al. Brain. 2018 Jan 1;141(1):13-36. doi: 10.1093/brain/awx189. Brain. 2018. PMID: 29053777 Free PMC article. Review.
Certain movement disorders are likely to associate with certain autoantibodies; for example, the characteristic dyskinesias, chorea and dystonia associated with NMDAR antibodies, stiff person spectrum disorders with GAD, glycine receptor, amphiphysin or DPPX antibodies, specific …
Certain movement disorders are likely to associate with certain autoantibodies; for example, the characteristic dyskinesias, chorea and dyst …
Nomenclature of Genetic Movement Disorders: Recommendations of the International Parkinson and Movement Disorder Society Task Force - An Update.
Lange LM, Gonzalez-Latapi P, Rajalingam R, Tijssen MAJ, Ebrahimi-Fakhari D, Gabbert C, Ganos C, Ghosh R, Kumar KR, Lang AE, Rossi M, van der Veen S, van de Warrenburg B, Warner T, Lohmann K, Klein C, Marras C; on behalf of the Task Force on Genetic Nomenclature in Movement Disorders. Lange LM, et al. Mov Disord. 2022 May;37(5):905-935. doi: 10.1002/mds.28982. Epub 2022 Apr 28. Mov Disord. 2022. PMID: 35481685 Review.
In 2016, the Movement Disorder Society Task Force for the Nomenclature of Genetic Movement Disorders presented a new system for naming genetically determined movement disorders and provided a criterion-based list of confirmed monogenic movement disorders. ...Movemen …
In 2016, the Movement Disorder Society Task Force for the Nomenclature of Genetic Movement Disorders presented a new system fo …
Sleep bruxism etiology: the evolution of a changing paradigm.
Klasser GD, Rei N, Lavigne GJ. Klasser GD, et al. J Can Dent Assoc. 2015;81:f2. J Can Dent Assoc. 2015. PMID: 25633110 Free article. Review.
Sleep bruxism is no longer considered a parasomnia nor is its etiology believed to be based on purely mechanical factors or psychological Issues. It is now considered to be primarily a sleep-related movement disorder with a yet to be determined multifactorial etiolo …
Sleep bruxism is no longer considered a parasomnia nor is its etiology believed to be based on purely mechanical factors or psychological Is …
Prevalence and clinical aspects of mild cognitive impairment in Parkinson's disease: A meta-analysis.
Baiano C, Barone P, Trojano L, Santangelo G. Baiano C, et al. Mov Disord. 2020 Jan;35(1):45-54. doi: 10.1002/mds.27902. Epub 2019 Nov 19. Mov Disord. 2020. PMID: 31743500 Review.
The present meta-analysis provides a robust estimate of prevalence rate of mild cognitive impairment in PD according to the Movement Disorder Society clinical criteria and to explore the differences between PD patients with and without mild cognitive impairment in d …
The present meta-analysis provides a robust estimate of prevalence rate of mild cognitive impairment in PD according to the Movement …
Gait Disorders.
Baker JM. Baker JM. Am J Med. 2018 Jun;131(6):602-607. doi: 10.1016/j.amjmed.2017.11.051. Epub 2017 Dec 27. Am J Med. 2018. PMID: 29288631 Review.
Magnesium supplementation for the treatment of restless legs syndrome and periodic limb movement disorder: A systematic review.
Marshall NS, Serinel Y, Killick R, Child JM, Raisin I, Berry CM, Lallukka T, Wassing R, Lee RW, Ratnavadivel R, Vedam H, Grunstein R, Wong KK, Hoyos CM, Cayanan EA, Comas M, Chapman JL, Yee BJ. Marshall NS, et al. Sleep Med Rev. 2019 Dec;48:101218. doi: 10.1016/j.smrv.2019.101218. Epub 2019 Oct 16. Sleep Med Rev. 2019. PMID: 31678660
Magnesium supplementation is often suggested for restless legs syndrome (RLS) or period limb movement disorder (PLMD) based on anecdotal evidence that it relieves symptoms and because it is also commonly recommended for leg cramps. ...
Magnesium supplementation is often suggested for restless legs syndrome (RLS) or period limb movement disorder (PLMD) based on …
Sydenham's Chorea.
Risavi BL, Iszkula E, Yost B. Risavi BL, et al. J Emerg Med. 2019 Jun;56(6):e119-e121. doi: 10.1016/j.jemermed.2019.02.012. Epub 2019 Apr 16. J Emerg Med. 2019. PMID: 31003820
BACKGROUND: Sydenham's chorea is the most common acquired movement disorder of adolescence. This clinical manifestation of acute rheumatic fever has a clear and documented relationship with Group A streptococcal infections. ...: Sydenham's chorea is a rare but impor …
BACKGROUND: Sydenham's chorea is the most common acquired movement disorder of adolescence. This clinical manifestation of acu …
Does the MDS-UPDRS provide the precision to assess progression in early Parkinson's disease? Learnings from the Parkinson's progression marker initiative cohort.
Regnault A, Boroojerdi B, Meunier J, Bani M, Morel T, Cano S. Regnault A, et al. J Neurol. 2019 Aug;266(8):1927-1936. doi: 10.1007/s00415-019-09348-3. Epub 2019 May 9. J Neurol. 2019. PMID: 31073716 Free PMC article.
OBJECTIVES: Developing disease modifying therapies for Parkinson's disease (PD) calls for outcome measurement strategies focused on characterizing early stage disease progression. We explored the psychometric evidence for using the Movement Disorder Society Unified …
OBJECTIVES: Developing disease modifying therapies for Parkinson's disease (PD) calls for outcome measurement strategies focused on characte …
3,797 results